We also divided the prostate cancer patients into “low severity” (n = 48) and “high severity” (n = 81) subgroups using a modified combination of Gleason score, TNM classification, and PSA levels in accordance with the 2015 NCCN (National Comprehensive Cancer Network) guidelines. This evidence concerns the gene PROS1 and prostate cancer.